The last half-decade has seen a rollercoaster of alterations to federal programs such as Medicare and Medicaid as the nation reeled, and then rebounded, from the COVID-19 pandemic.
The changes include Medicaid eligibility requirements and a process called Medicaid unwinding. A study out of the Rand Corporation and conducted by a Pittsburgh researcher found that this process of disenrolling people from Medicaid was linked to fewer prescriptions for an opioid use disorder medication that helps prevent relapse and keep people in recovery.
Some warn the findings are a grim sign that fewer people are in treatment at a time when federal policies are further clinching resources for addiction.
While 71 million Americans are enrolled in Medicaid, that number has dropped from 87 million patients in the last two years, according to a Kaiser Family Foundation Analysis, although it’s up slightly from pre-pandemic estimates. Medicaid is also a key payer for medications that treat opioid use disorder and prevent relapse.
The passage of President Donald Trump’s One Big Beautiful Bill in July will cut Medicaid coverage by nearly $1 trillion over the next 10 years, leaving millions of Americans at risk of losing health coverage.
What is buprenorphine?
Buprenorphine is a medicine prescribed for opioid use disorder that helps people manage cravings and withdrawal symptoms. It achieves this by partially activating the brain’s opioid receptors.
Without medications for opioid use disorder (OUD), many find it very difficult, if not impossible, to stop using substances like fentanyl.
One study, published in 2024 in the Western Journal of Emergency Medicine, by Texas researchers that examined health records of people OUD, found those who took buprenorphine were both more likely to survive and to stay sober from opioids compared to their counterparts who did not take the medication.
Pre-pandemic, commercial insurers were the top payers for buprenorphine; post-pandemic, that shifted to Medicaid, with prescriptions continuing to grow monthly, a U.S. Department of Health and Human Services study published in 2023 found.
Despite these increases, buprenorphine prescribing did not keep up with the rise in overdose deaths over the past two years, researchers also found.
“Medicaid is the single largest payer for opioid use disorder, so this [RAND study] is a big deal,” said Paul Joudrey, assistant professor at the University of Pittsburgh’s Division of General Internal Medicine and an addiction medicine specialist and buprenorphine treatment provider.
What is the Medicaid unwinding?
Known as the continuous enrollment condition, certain federal exceptions during the COVID-19 pandemic allowed Americans to maintain their Medicaid coverage to ensure they had health care during a time when they may not have been working.
That process ended on March 31, 2023, and the process of reinstating previous eligibility requirements began. Medicaid unwinding refers to the scaling back of those exceptions, leading to disenrollment of millions from the program. States have pursued this process differently, with some more active than others.

In Pennsylvania, tens of thousands of Medicaid patients were disenrolled from their plans from May 2023 to May 2024. This could be because they were deemed ineligible or due to a procedural reason, such as a lack of response from patients, amounting to more than 600,000 Pennsylvanians losing coverage, per state data.

What did the RAND study find?
RAND researchers, knowing that medication for opioid use disorder has been crucial for reducing overdose deaths, wanted to learn more about the extent to which Medicaid unwinding impacted people’s treatment. Based in California, the research nonprofit has an office in Pittsburgh’s Oakland neighborhood.
Published in the September/October issue of the Journal of Addiction Medicine, the study examined buprenorphine prescriptions dispensed at pharmacies across all U.S. states from 2021 to 2023. These prescriptions were part of a large database that tracks a variety of health care claims, including hospital and cancer data.
In states with the greatest unwinding activity, patients had their buprenorphine treatments canceled at more than double the rate than those in states with less unwinding, the study found.
Treatment was also less likely to be paid for by Medicaid six months after unwinding, compared to six months before. In states with high levels of unwinding, fewer people started treatment for opioid use disorder.
Researchers were able to factor out buprenorphine prescribed for pain, zeroing in on a population using it exclusively for opioid use disorder.
“The opioid crisis has been with us for too long, and it has continued to evolve,” said Bradley Stein, senior author on the paper, senior physician policy researcher at RAND and a Pittsburgh-based child psychiatrist.
“As people are losing Medicaid coverage, for many of those people it may disrupt the treatment of their opioid disorder, or may prevent starting treatment that Medicaid would have covered otherwise.”
Joudrey, the Pitt professor, thought the study was timely and in line with what he observes when treating patients.
“It’s concerning, and it fits a larger pattern,” he said.
Joudrey has watched patients fall out of his care after being disenrolled from Medicaid. Many times, the patients don’t know why they have been disenrolled and have otherwise been doing well in treatment, he said. But if they lose access to buprenorphine, they may relapse, go back out on the street or otherwise disappear from Joudrey’s medical supervision.
“I'll see it almost every day I’m in clinic, frankly, some sort of issue around insurance and Medicaid problems,” he said. “I’ve seen it hurt people. For a provider, it’s really disheartening.”
Current Medicaid requirements also create tricky catch-22s for people seeking treatment for addiction, said Joudrey. He has seen his patients, for instance, pass on a well-paying job because they will make more money than is allowed for their buprenorphine prescription to be covered — yet not enough to pay for it out of pocket. Or it will lead them to be kicked off Medicaid entirely. The price of buprenorphine varies by dose, but the average dose for people with opioid use disorder costs about $135 out of pocket, and up to $500 for a larger supply based on various estimates.
“This really does come up. This is not like a theoretical thing,” he said. “I have seen firsthand, this affects patients’ decision-making in terms of the jobs they take, the treatment they accept. I’ve seen patients take less buprenorphine because they’re worried about affording the full dose without Medicaid. I’ve seen it. I mean, there is a real cost to these issues.”
He added that he understands the concern over the growth of Medicaid costs, but said these policies seem to unintentionally punish the most vulnerable.
Stein said because Medicaid is a main payer for those with substance use disorders, he and his team weren’t surprised to see the outcomes they did, but were disheartened that the trend of losing Medicaid was not compensated by people transferring to commercial insurance.
“We had sort of hoped that these people were finding their way to commercial insurance or had resources from themselves or their family or others that might have been able to sort of mitigate this impact,” he said.
He pointed out a few limitations of the study, including that researchers could not see individual information about these Medicaid patients, so they didn’t know why treatment had ceased, or any additional care patients may have been receiving for their substance use disorder.
“We don't know at an individual level that the reason the individual stopped [buprenorphine] was because they lost Medicaid coverage,” he said. “They could have stopped treatment because they had achieved what they needed to recover. There are lots of reasons.”
And Joudrey noted the correlation of Medicaid unwinding and a drop in buprenorphine prescribing is just that — a correlation — although he found it compelling and said it aligns with past research on the same trends.
Stein also said the window of time researchers had access to following the unwinding was short, and they may have gleaned more information if that window was longer.
What happens now?
Stein hopes to ultimately see more clinicians sign on to prescribe buprenorphine to fill provider gaps from burnout and stigma. He also hopes states are proactive about protecting vulnerable patients.
“It’s really up to states and communities to think about how they may be able to be sure that these people continue to receive effective treatment that can change their lives, that allow them to take care of their children, to allow to take care of their parents, and over time to enter recovery, stay in the workforce or go back to school,” said Stein
Joudrey, on the other hand, is not optimistic. He worries about those with substance use disorders being unintentionally punished by further policy changes.
In a December 2023 report, the Centers for Medicare and Medicaid Services encouraged states to preserve Medicaid coverage in a variety of ways. States could set up auto-renewal for coverage, work to reduce call center wait times or instate waivers to allow people on supplemental assistance, or food stamps, to be eligible for Medicaid.
That tone of encouragement has shifted with the Big Beautiful Bill, which cuts funding for Medicaid and adjusts work requirements, in that patients should report their work status every six months instead of every year.
It will take more attention and more funding to divert the right resources toward reducing poor outcomes from addiction, said Stein.
“Yes, fatal overdoses have decreased, but without concerted efforts — and one of those efforts is treatment — it’s not like the problem has gone away.”






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.